IMUNON Reports Strong Phase 3 OVATION 3 Enrollment Progress as IMNN-001 Shows Promise in Advanced Ovarian Cancer Treatment
Key Insights
IMUNON's Phase 3 OVATION 3 study evaluating IMNN-001 in combination with standard chemotherapy for newly diagnosed advanced ovarian cancer (search) continues to advance enrollment toward future BLA filing.
Previous Phase 2 OVATION 2 data demonstrated a 13-month extension in median overall survival with IMNN-001, showing a hazard ratio of 0.70 in the intent-to-treat population.
New minimal residual disease (MRD) study data reveals IMNN-001's mechanism of action, showing IL-12 (search) production by macrophages and tumor microenvironment remodeling that transforms "cold" tumors into "hot" ones.
IMUNON, Inc. (Nasdaq: IMNN) has reported significant progress in its pivotal Phase 3 OVATION 3 study, advancing enrollment for IMNN-001 in combination with standard-of-care neoadjuvant and adjuvant chemotherapy for women with newly diagnosed advanced ovarian cancer (search). The company announced that enrollment continues to generate strong interest from investigators and the medical community, positioning IMUNON closer to a future Biologics License Application (BLA) filing.
Phase 2 Results Drive Phase 3 Momentum
The enthusiasm for OVATION 3 builds on compelling Phase 2 OVATION 2 study results, where IMNN-001 demonstrated a 13-month extension in median overall survival in the intent-to-treat population with a hazard ratio of 0.70. In patients receiving PARP inhibitors as maintenance therapy, the median overall survival in the IMNN-001 arm has not yet been reached, with all patients having surpassed 31 months of follow-up and numerous patients progressing beyond five years, compared to 37 months in the control arm (hazard ratio of 0.42).
These results, presented at ASCO and published in Gynecologic Oncology, highlight IMNN-001's potential to redefine frontline treatment in a field where no meaningful advances have occurred in over 30 years.
Mechanism of Action Revealed Through MRD Study
New data from IMUNON's ongoing minimal residual disease (MRD) study, conducted in partnership with Break Through Cancer (search), provides insights into IMNN-001's mechanism of action. The translational data demonstrate the therapy's broad impact on the tumor microenvironment, with definitive evidence that treatment leads to IL-12 (search) production by macrophages in tumor tissue, boosting T cell cytotoxic functions.
Specifically, IMNN-001 induces robust expression of IL12A (search) and IL12B (search) in macrophages of peritoneal fluid and tumor tissue, stimulating a cascade of anti-tumor cytokines, including interferon-gamma, and resulting in potent macrophage and T cell activation. The tumor immune microenvironment becomes more inflamed following exposure to IMNN-001, effectively turning "cold" tumors "hot" by activating both innate and adaptive immune systems.
Promising Clinical Readouts and Safety Profile
Preliminary clinical readouts from the MRD study show encouraging results, including a lower MRD positivity rate, a lower percentage of tumor-containing biopsies in MRD-positive patients, higher complete response scores at cytoreduction, and a higher probability of progression-free survival with IMNN-001 compared to the control arm.
The positive tolerability profile of IMNN-001 continues across studies, including in combination with standard-of-care chemotherapy plus bevacizumab and in the maintenance setting, with no cytokine release syndrome, systemic toxicities, or serious immune-related adverse events observed.
TheraPlas Platform Technology
IMUNON's TheraPlas platform enables localized, durable expression of interleukin-12 (search) (IL-12 (search)) and other therapeutic payloads. By targeting the tumor site directly, this approach avoids the toxicities of systemic immunotherapies while remodeling the microenvironment to generate anti-tumor responses. The company has completed extensive animal experiments with IMNN-001 in additional tumor types and TheraPlas for other DNA plasmid delivered payloads.
Addressing Significant Unmet Need
The therapy targets ovarian cancer (search), a disease affecting 20,000 women annually in the U.S. and 300,000 worldwide, characterized by high recurrence rates and low five-year survival rates. IMNN-001 has received Fast Track and Orphan Drug designations from the FDA.
2026 Outlook
Looking ahead to 2026, IMUNON anticipates continued enrollment in OVATION 3 with interim analyses potentially enabling early stopping and BLA filing in the HRD+ population. The company estimates $30 million in funding needed for the OVATION 3 trial with focus on the HRD+ subgroup, with options for expansion. Additional data presentations at major conferences and further translational insights from OVATION 2 tumor samples are expected.